NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Propionic Acid in Multiple Sclerosis

CompletedPhase 2, Phase 3

Sponsor: Salzburger Landeskliniken

Conditions: Multiple Sclerosis

Interventions: Propionic acid 1000 mg capsule, Placebo

Countries: Austria

The purpose of this study is to demonstrate the superiority of propionic acid over placebo as add on treatment in multiple sclerosis (MS).

Eligibility overview

Sex: ALL

Age: 18 Years to 60 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of multiple sclerosis (MS)
* Clinically and radiologically stable MS in the previous 3 months
* Age between 18 and 60 years
* Positive finding for oligoclonal bands (OCBs)
* Written consent
* Blood collection at the beginning and end of the study for routine parameter examination as well as sample preservation (especially for measuring propionic acid levels)
* Negative pregnancy test for female participants of childbearing age

Exclusion Criteria:

* Existing propionic acid supplementation
* Change in disease-modifying therapy (DMT) in the previous 4 weeks
* Existing severe systemic diseases
* Presence of other concomitant structural nerve diseases (e.g., polyneuropathy, brain tumor, strokes)
* High JCV titer under Natalizumab

Locations (1)

Salzburg, State of Salzburg, Austria